LONDON (Reuters) – Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Martin Holst Lange, Novo Nordisk’s head of development, made the comments to Reuters in an interview after the company released better-than-expected third-quarter results.
The Danish drugmaker is due to release data from a late-stage trial of CagriSema, a two-drug combination obesity treatment that like its popular obesity drug Wegovy is injected, by the end of 2024.
(Reporting by Maggie Fick; Editing by Jan Harvey)
Comments